PRUDENTIAL FINANCIAL INC (PRU)
Sector: Financials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Financials
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PRU
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRU | Executive Vice President and CFO | 59 | ["Executive Vice President and CFO of Johnson & Johnson since 2018", "Member of Johnson & Johnson\u2019s Executive Committee", "Oversaw the separation of the Company\u2019s Consumer Health business", "Served on the Kenvue board from 2023 to 2024", "Various leadership positions at Johnson & Johnson", "Accounting roles at AMETEK, Inc.", "global finance expertise", "stakeholder engagement"] | ["Audit", "Finance"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| KVUE | EVP, Chief Financial Officer of Johnson & Johnson; Director | 57 | ["Deep understanding of the consumer health business","Broad expertise in management, strategy, finance and operations","Substantial experience in the healthcare industry","Strong commitment to business innovation, talent development and purpose-based leadership"] | [] | 2024 |
Biography sourced from the proxy statement filing.
Age: 59 Director Since: September 2025 Prudential Committees: Audit Finance Former Directorships Held During the Past Five Years: Kenvue (December 2024) Mr. Wolk has been the Executive Vice President and CFO of Johnson & Johnson (a multinational pharmaceutical, biotechnology, and medical technologies corporation) since 2018. He is also a member of Johnson & Johnson s Executive Committee and was the sponsor overseeing all capital markets and operational aspects of the separation of the Company s Consumer Health business into an independent, publicly traded company, Kenvue. He served on the Kenvue board from 2023 to 2024 while Johnson & Johnson held an equity interest in the company. Previously, Mr. Wolk served in various leadership positions at Johnson & Johnson as well as at AMETEK, Inc. in a variety of accounting roles.